Haymarket Media, Inc.

Issue Archive | About Us | Contact Us | Subscribe | Editorial Board | Author Guidelines | About Haymarket Media

ONA

Subscribe to our RSS feeds

RSS | Login | Register

CLOSE

Register for your FREE account now and join thousands of oncology professionals who stay informed about patient care issues, practical oncology-care management techniques, and drug administration and dosage information.

Email*

Password*

Keep me logged in Forgot your password?

Email*

Register now »

Clinical Trials: A Phase I/II Study of Gleevec® Combined With Panitumumab (Vectibix®) in Patients Prescreened for C-kit/PDGFr Activated Pathways Using a Proteomic Based Assay

January 06, 2010

Print
Email
Reprint
Text: A | A | A

More Colorectal Cancer Clinical Trials

More in Colorectal Cancer Clinical Trials:

Clinical Trials: A Randomized, Multicenter, Phase 2 Study to Compare the Efficacy of Panitumumab in Combination With mFOLFOX6 to the Efficacy of Bevacizumab in Combination With mFOLFOX6 in Patients With Previously Untreated, KRAS Wild-Type, Unresectable, M

Sponsor and Collaborators
Inova Health Care Services
Novartis Pharmaceuticals

Contacts
Joy Wiedemann, RN, BSN
703-776-4304
joy.wiedemann@inova.org

Stacey Banks, CCRC
703-776-3565
stacey.banks@inova.org

Principal Investigator
Kirsten Edmiston, MD, FACS
Inova Fairfax Hospital Cancer Center

ClinicalTrials.gov Identifier
NCT00867334

You must be a registered member of ONA to post a comment.

Click here to login | Click here to register

Web Exclusives

Posttransplant lenalidomide can slow down multiple myeloma

Delicia Honen Yard May 29, 2012

Lenalidomide use after autologous stem-cell transplant significantly improved progression-free and overall survival in patients with myeloma.

Melanoma genome study implicates sun and new genetic culprits

Delicia Honen Yard May 28, 2012

Genetic mutations increased along with chronic sun exposure in persons with melanoma, and yet another gene may contribute to disease risk as well.

Modified stem cells keep glioblastoma at bay

Delicia Honen Yard May 25, 2012

Three patients with glioblastoma lived longer than predicted after receiving transplants of their own blood stem cells that had been gene-modified.

Oncology Nurse Advisor Sitemap

Other Haymarket Medical Websites

MPR (drug database)

Clinical Advisor

JAAPA

myCME - Online CME

McKnights Long Term Care News

Renal and Urology News

Chemotherapy Advisor

International

GPonline

MIMS (drug database)

© 2012 Haymarket Media, Inc.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions